Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CF33-CD19 + blinatumomab
- Development stage
- Unknown
- Lead developer
- Imugene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
CF33-CD19 + blinatumomab is a combination therapy under clinical investigation for advanced or metastatic solid tumors. CF33-CD19 is a novel chimeric oncolytic poxvirus that selectively infects and lyses tumor cells and has been engineered to express a truncated, non-signaling form of human CD19 on the surface of infected tumor cells. This viral tagging enables the use of CD19-directed therapies, including bispecific T-cell engagers such as blinatumomab. Blinatumomab is a bispecific monoclonal antibody that binds CD19 and CD3, activating T cells to recognize and destroy CD19-expressing tumor cells. This combination aims to enable "targetless" solid tumors to be attacked by T cells through synthetic CD19 expression and BiTE-mediated T cell redirection. The combination is in phase I dose escalation/expansion trials with intravenous (IV) and intratumoral (IT) administration, with endpoints including safety, tolerability, and demonstration of anti-tumor activity[1][2][4][5][7][9].
- Brand names
- Blincyto (blinatumomab)
- Other names
- CF33-CD19 + blinatumomab
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CF33-CD19 + blinatumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CF33-CD19 + blinatumomab.